HK1060571A1 - Quinazoline derivatives, medicaments containing said compounds, their utilization and method for theproduction thereof - Google Patents

Quinazoline derivatives, medicaments containing said compounds, their utilization and method for theproduction thereof

Info

Publication number
HK1060571A1
HK1060571A1 HK04103590A HK04103590A HK1060571A1 HK 1060571 A1 HK1060571 A1 HK 1060571A1 HK 04103590 A HK04103590 A HK 04103590A HK 04103590 A HK04103590 A HK 04103590A HK 1060571 A1 HK1060571 A1 HK 1060571A1
Authority
HK
Hong Kong
Prior art keywords
theproduction
utilization
compounds
quinazoline derivatives
medicaments containing
Prior art date
Application number
HK04103590A
Inventor
Frank Himmelsbach
Elke Langkopf
Stefan Blech
Birgit Jung
Elke Baum
Flavio Solca
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1060571(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HK1060571A1 publication Critical patent/HK1060571A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK04103590A 2000-12-20 2004-05-20 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for theproduction thereof HK1060571A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (en) 2000-12-20 2000-12-20 Chinazoline derivatives, pharmaceuticals containing these compounds, their use and process for their preparation
PCT/EP2001/014569 WO2002050043A1 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof

Publications (1)

Publication Number Publication Date
HK1060571A1 true HK1060571A1 (en) 2004-08-13

Family

ID=7667887

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103590A HK1060571A1 (en) 2000-12-20 2004-05-20 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for theproduction thereof

Country Status (40)

Country Link
EP (2) EP1345910B9 (en)
JP (1) JP3827641B2 (en)
KR (1) KR100852102B1 (en)
CN (1) CN1277822C (en)
AR (1) AR040524A1 (en)
AT (1) ATE430136T1 (en)
AU (2) AU2002219174B2 (en)
BE (1) BE2014C009I2 (en)
BG (1) BG66139B1 (en)
BR (1) BRPI0116266B8 (en)
CA (1) CA2432428C (en)
CY (2) CY1109290T1 (en)
CZ (1) CZ302721B6 (en)
DE (2) DE10063435A1 (en)
DK (1) DK1345910T3 (en)
EA (1) EA006317B1 (en)
EE (1) EE05244B1 (en)
ES (1) ES2326617T3 (en)
FR (1) FR14C0009I2 (en)
HK (1) HK1060571A1 (en)
HR (1) HRP20030504B1 (en)
HU (2) HU228874B1 (en)
IL (2) IL156277A0 (en)
LT (1) LTC1345910I2 (en)
LU (1) LU92370I2 (en)
ME (1) ME02777B (en)
MX (1) MXPA03005559A (en)
MY (1) MY136086A (en)
NO (2) NO325672B1 (en)
NZ (1) NZ526918A (en)
PL (1) PL214798B1 (en)
PT (1) PT1345910E (en)
RS (1) RS50860B (en)
SI (1) SI1345910T1 (en)
SK (1) SK287573B6 (en)
TW (1) TWI295992B (en)
UA (1) UA74614C2 (en)
UY (1) UY27078A1 (en)
WO (1) WO2002050043A1 (en)
ZA (1) ZA200304141B (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1166645C (en) 1999-06-21 2004-09-15 贝林格尔英格海姆法玛两合公司 Bicyclic heterocycles, medicaments contg. these compounds, their use and methods for prodn. thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (en) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (en) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
PE20040945A1 (en) * 2003-02-05 2004-12-14 Warner Lambert Co PREPARATION OF SUBSTITUTED QUINAZOLINES
DE10307165A1 (en) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (en) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Process for the preparation of aminocrotonyl compounds
CN1972688B (en) * 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-phenylamino-quinazolin-6-yl-amides
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR100832593B1 (en) * 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an signal trnasduction inhibitor and method for the preparation thereof
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
JP2009515852A (en) 2005-11-11 2009-04-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy of cancer containing EGFR / HER2 inhibitor
ES2397181T3 (en) 2006-01-26 2013-03-05 Boehringer Ingelheim International Gmbh Procedure for preparing quinazoline derivatives substituted with aminocrotonylamino
PT2068880E (en) 2006-09-18 2012-07-12 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
KR20100111291A (en) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
CN102088979B (en) 2008-05-13 2013-10-16 阿斯利康(瑞典)有限公司 Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin-4-yl] oxy}quinazoline
UY31867A (en) 2008-06-06 2010-01-29 Boehringer Ingelheim Int NEW SOLID PHARMACEUTICAL FORMULATIONS THAT INCLUDE BIBW 2992
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TWI385174B (en) * 2008-11-10 2013-02-11 Nat Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
JP2012515184A (en) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング How to treat colorectal cancer
JP2012526766A (en) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング A novel combination therapy in the treatment of neoplastic and fibrotic diseases
EP2429527A1 (en) * 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of cancer and fibrotic diseases
LT2451445T (en) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
EP2509592A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
CN102686581B (en) * 2009-12-21 2015-08-26 张强 Quinazoline derivant
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
NO2608792T3 (en) 2010-08-26 2018-03-10
EP2643314B1 (en) * 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
EP2680850B1 (en) 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
WO2012155339A1 (en) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
CN102838590B (en) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 Amino quinazoline derivative and application thereof in preparation of antineoplastic drugs
US20150232457A1 (en) 2011-10-06 2015-08-20 Ratiopharm Gmbh Crystalline forms of afatinib di-maleate
CN103073539B (en) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(substituted benzene amino) quinazoline derivant and preparation method thereof, pharmaceutical composition and purposes
ES2613399T3 (en) 2012-01-17 2017-05-24 Astellas Pharma Inc. Pyrazincarboxamide Compound
CN103772380A (en) * 2012-10-23 2014-05-07 杨子娇 Type of compounds for treating narrow chamber angle and use of compounds
US20150368230A1 (en) 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105377266A (en) 2013-04-18 2016-03-02 勃林格殷格翰国际有限公司 Pharmaceutical composition, methods for treating and uses thereof
CN103254183B (en) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 Ah method is for the preparation method of Buddhist nun
WO2014180271A1 (en) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 Method for preparing afatinib and intermediate thereof
CN103254182A (en) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 Method for preparing Afatinib
WO2014183560A1 (en) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 Afatinib and preparation method of intermediate thereof
CN103242303B (en) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 Afatinib preparation method
CN104513229A (en) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 Quinazoline derivatives and preparation method thereof
CN103755688B (en) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 A kind of Ah method is for the preparation method of Buddhist nun's compound
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EA031059B1 (en) 2014-01-02 2018-11-30 Тева Фармасьютикалз Интернэшнл Гмбх Crystalline form alpha of afatinib di-maleate
CN105315263B (en) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 The synthetic method of afatinib intermediate
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (en) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 One maleate crystal form of Afatinib and preparation method thereof and pharmaceutical composition
RU2720810C2 (en) * 2015-03-20 2020-05-13 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Salts of a quinazoline derivative and a method for production thereof
CN105175400B (en) * 2015-09-29 2018-04-10 河北神威药业有限公司 A kind of preparation method of afatinib intermediate
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (en) * 2016-10-21 2019-05-24 河北神威药业有限公司 A kind of detection method of the intermediate for preparing Afatinib and its enantiomter
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
WO2019126136A2 (en) * 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
CN110437163A (en) * 2018-05-03 2019-11-12 斯特恩格林公司 Pyrimidines as tyrosine kinase inhibitor
CN113382986A (en) 2018-09-25 2021-09-10 黑钻治疗公司 Tyrosine kinase inhibitor compositions, methods of making and methods of using the same
CN109265449B (en) * 2018-11-07 2021-11-23 沈阳工业大学 EGFR and HER2 double-target tyrosine kinase inhibitor and preparation method and application thereof
BR112021011894A2 (en) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited PHARMACEUTICAL COMPOSITION
CN109824657A (en) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 Two maleic acid Afatinib novel crystal forms of one kind and its preparation method and application
CN110590682A (en) * 2019-10-14 2019-12-20 重庆医科大学 Method for preparing afatinib impurity and prepared impurity
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0892789T2 (en) * 1996-04-12 2010-03-31 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
DE19908567A1 (en) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE19911366A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
CN1341104A (en) * 1999-02-27 2002-03-20 贝林格尔英格海姆法玛公司 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911509A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
CN1166645C (en) * 1999-06-21 2004-09-15 贝林格尔英格海姆法玛两合公司 Bicyclic heterocycles, medicaments contg. these compounds, their use and methods for prodn. thereof
EP1280798B1 (en) * 2000-04-08 2007-01-03 Boehringer Ingelheim Pharma GmbH & Co.KG Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them

Also Published As

Publication number Publication date
NO2014003I1 (en) 2014-06-02
YU49603A (en) 2006-05-25
TWI295992B (en) 2008-04-21
ATE430136T1 (en) 2009-05-15
HRP20030504B1 (en) 2011-09-30
NO20032726D0 (en) 2003-06-16
BRPI0116266B8 (en) 2021-07-27
JP2004516283A (en) 2004-06-03
EE05244B1 (en) 2009-12-15
FR14C0009I1 (en) 2014-03-07
MY136086A (en) 2008-08-29
PL361798A1 (en) 2004-10-04
EE200300300A (en) 2003-10-15
NO2014003I2 (en) 2015-10-19
CN1481370A (en) 2004-03-10
CA2432428C (en) 2009-09-01
FR14C0009I2 (en) 2014-11-14
BE2014C009I2 (en) 2021-02-04
LTPA2014005I1 (en) 2022-05-25
LU92370I2 (en) 2014-03-31
JP3827641B2 (en) 2006-09-27
CY2014008I2 (en) 2015-12-09
AU1917402A (en) 2002-07-01
SI1345910T1 (en) 2009-08-31
EA006317B1 (en) 2005-10-27
CZ20031930A3 (en) 2003-10-15
NO325672B1 (en) 2008-07-07
IL156277A (en) 2009-12-24
BG66139B1 (en) 2011-07-29
BR0116266A (en) 2004-02-17
HU228874B1 (en) 2013-06-28
UY27078A1 (en) 2002-07-31
ME02777B (en) 2011-10-10
ES2326617T3 (en) 2009-10-16
MXPA03005559A (en) 2004-10-14
EP1345910B9 (en) 2014-06-04
PL214798B1 (en) 2013-09-30
PT1345910E (en) 2009-07-14
DK1345910T3 (en) 2009-07-20
HUP0301852A2 (en) 2003-09-29
UA74614C2 (en) 2006-01-16
HUS1400005I1 (en) 2017-08-28
CZ302721B6 (en) 2011-09-21
SK287573B6 (en) 2011-03-04
EP1345910B1 (en) 2009-04-29
CN1277822C (en) 2006-10-04
NO20032726L (en) 2003-06-16
RS50860B (en) 2010-08-31
CY2014008I1 (en) 2014-07-02
KR20030071787A (en) 2003-09-06
EA200300671A1 (en) 2004-06-24
ES2326617T9 (en) 2014-09-10
DE10063435A1 (en) 2002-07-04
LTC1345910I2 (en) 2022-06-10
SK7712003A3 (en) 2003-10-07
BRPI0116266B1 (en) 2017-10-31
BG107929A (en) 2005-01-31
DE50114874D1 (en) 2009-06-10
CY1109290T1 (en) 2014-07-02
WO2002050043A1 (en) 2002-06-27
ZA200304141B (en) 2004-04-15
HRP20030504A2 (en) 2005-06-30
AU2002219174B2 (en) 2007-09-06
MEP59508A (en) 2011-05-10
EP1345910A1 (en) 2003-09-24
HUP0301852A3 (en) 2008-03-28
NZ526918A (en) 2006-11-30
LU92370I9 (en) 2019-01-17
EP2112140A1 (en) 2009-10-28
CA2432428A1 (en) 2002-06-27
IL156277A0 (en) 2004-01-04
AR040524A1 (en) 2005-04-13
KR100852102B1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
HK1060571A1 (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for theproduction thereof
AU2002219174A1 (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
HUP0203425A3 (en) Quinazoline derivatives, process for their preparation and their use
IL140078A0 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
HUP0104964A3 (en) Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing the compounds
HUP0105478A3 (en) 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
HUP0401081A3 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
HUP0002893A3 (en) Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0201832A3 (en) Quinazoline derivatives, pharmaceutical compositions containing these compounds, and processes for preparing them
HK1044338A1 (en) 5-Pyridyl-1, 3-azole compounds, process for producing the same and use thereof
HUP0201711A3 (en) N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them
TWI319764B (en) Mercaptoacetylamide derivatives, a process for their preparation and their use
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
HK1049655B (en) Substituted norbornylamino derivatives, production and use thereof and medicaments containing them
HUP0103303A3 (en) Imidazole compounds, process for producing them, their use and medicaments containing them
AU2001258200A1 (en) Synthetic derivatives of lunularic acid, medicaments containing said compounds, method for producing the lunularic acid derivatives and the use thereof
HUP0200376A3 (en) Thiaoloindolinone compounds, process for their preparation and pharmaceutical composions containing them and their use
HUP0000920A3 (en) Pde4 inhibitor isoquinolinylidene derivatives, process for their preparation and medicaments containing them
IL156160A0 (en) Klainetins and their derivatives, method for their preparation and use thereof
HU9900123D0 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
HUP0203129A3 (en) Aromatic di-keto derivatives, process for producing them and use them as pharmaceuticals
HUP0204393A3 (en) Pluraflavins and derivatives thereof, process for their preparation and use thereof
HUP0000919A3 (en) Pde4 inhibitor isoquinolinydene-derivatives, process for their preparation and medicaments containing them
HU0001178D0 (en) New propene-carbon acid-amidoxim derivatives, process for their production and medicaments containing the same

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211211